1 is a disorder of energy use and storage, diagnosed by co-occurrence of at least 3 of 5 of the following medical conditions: abdominal (central) obesity, hypertension, elevated fasting-plasma glucose, high triglycerides, and low high-density lipoprotein cholesterol levels. Clinically, MetS is strongly associated with increased risk of cardiovascular disease and type-2 diabetes mellitus.
Studies in Humans
Tissue biopsies were collected from 2 patients' cohorts. MR/PTGDS expression analysis in mature adipocyte fraction (MAF) was performed on patients recruited from Geoffroy Saint-Hilaire Clinic in Paris, France (ethical approval number, CPP1704201, Paris). This group of patients was composed by 9 nonobese (body mass index, 26±1.3 kg/m 2 ) and 12 obese (body mass index, 38±3.3 kg/m 2 ) subjects undergoing plastic or gastric surgery (n=12), selected as previously described.
11
MR/PTGDS expression analysis in subcutaneous adipose tissue (SAT) and visceral adipose tissue (VAT) was performed in patients enrolled by the Nancy University Hospital Clinical Investigation Center (ethical approval number, CPP3.07.01). 12 This group of patient was composed by 21 morbidly (grade III) obese subjects (age, 44.5±1.8 years; body mass index, 47.6±1.3 kg/m 2 ) undergoing bariatric surgery.
Patient experimental procedures were conducted in accordance with the guidelines of the Ethics Committees of the 2 hospitals, and all subjects gave their informed consent to participate in the study. Clinical investigations were performed in accordance with the Declaration of Helsinki as revised in 2000 (http://www.wma.net/e/ policy/b3.htm).
Statistics
Data analysis and representation were accomplished by using GraphPad Prism 6 software. Results are reported as mean±SEM for the indicated number of cells, animals, and human patients unless otherwise indicated. Statistical analyses were performed as indicated by Mann-Whitney t test, 1-way ANOVA test followed by Newman-Keuls multi comparison correction test or 2-way ANOVA test followed by Fisher least significant difference multicomparison correction test. The Spearman correlation was computed to analyze the association between 2 variables. Sigmoidal 4-grades polynomial interpolation was used to calculate the median effective dose (ED 50 ) in dose-response experiments.
Results

MR Expression Is Increased in Mouse and Human Adipose Tissues in Obese Patients
In obese patients, MR mRNA expression was significantly higher in VAT when compared with SAT (relative MR mRNA level: SAT, 1.0±0.1 and VAT, 1.9±0.3; n=21; P<0.01). MR mRNA expression was increased by 2-to 3-fold in SAT and VAT of db/db mice when compared with db/+ control littermates ( Figure 1A and 1B). MAF isolated from both db/db and human adipose tissues exhibited higher MR mRNA levels in mature adipocytes isolated from obese mice and obese subjects in comparison with db/+ mice and lean human controls, respectively ( Figure 1C and 1D) .
To understand the pathophysiological role of the MR increase in mature adipocytes, we generated a mouse model (hereafter called adipo-MROE mice) allowing conditional and inducible increase of MR expression in adipocytes ( Figure  S1 in the online-only Data Supplement). Three-or 12 weekinduction of transgene expression with doxycycline led to a 2-to 3-fold increase in MR expression in SAT, VAT, and MAF of adipo-MROE mice (Figure S1B-S1D; Figure S2 with their control littermates (thereafter called control-MR littermates). These results indicate that our mouse model mimics changes in adipose tissue MR expression observed in human and db/db mice. Doxycycline treatment did not affect MR expression in other tissues, such as heart, kidney, liver, and pancreas ( Figure S3 ).
Adipo-MROE Mice Display Features of MetS
Adipo-MROE mice fed with regular chow diet for 12 weeks had a progressive increase in BW when compared with control-MR littermates ( Figure 2A ). This was associated with an increase in VAT mass (Table) and adipocyte hypertrophy as evidenced by histological analysis of VAT sections ( Figure 2B ). Interestingly, the increase in adipocyte area was positively correlated with an increase in MR expression in VAT (Spearman correlation, r, 0.71; P<0.01; Figure 2B , inset). Food and calories intake were similar between adipo-MROE mice and their littermate controls ( Figure S4A -S4C).
Fasting-plasma insulin concentration and HOMA index increased in 12-week-old adipo-MROE mice fed with regular chow when compared with control-MR littermates (Table) . Hypertriglyceridemia and hypercholesterolemia were also evident in adipo-MROE mice (Table) . Blood pressure levels were similar between adipo-MROE and their littermate controls at 4 weeks ad 12 weeks after transgene induction (Table) . Aldosteronemia was not affected in adipo-MROE mice when compared with littermate controls (aldo [pg/mL]:
control-MR, 431±44; adipo-MROE, 387±29; P=not significant; Mann-Whitney t test; n=5-7). Glucose homeostasis was assessed by fasting-intraperitoneal ITT and GTT. Adipo-MROE mice showed impaired physiological responses to insulin and glucose challenge ( Figure 2C and 2D). The analysis of plasma insulin concentrations during GTT, which takes into account the endogenous release of insulin to counteract glucose challenge, revealed a higher peak of insulin at 15 minutes in adipo-MROE mice compared with their control-MR littermates ( Figure 2E ). This indicates that adipo-MROE mice are insulin resistant and need more insulin to normalize their glycaemia. To discriminate between metabolic effects related to increased body mass per se or to increased adipocyte MR expression, ITT and GTT tests were performed after 3 weeks of MR overexpression only, when control-MR and adipo-MROE mice still have comparable weights (g; control-MR: 30.4±2.4 and adipo-MROE: 32.5±2.3; n=8; P=not significant). When compared with control-MR littermates, adipo-MROE mice presented an impaired ITT and normal GTT ( Figure 3A and 3B). A nonsignificant increase in HOMA index was observed (HOMA index: control-MR: 6.7±0.8; adipo-MROE: 11.2±2.3; P=not significant; Mann-Whitney t test; n= 8). In vivo MR antagonism with canrenoate prevented the effect on ITT ( Figure 3C and 3D). Therefore, an increase in MR expression in adipocytes leads to insulin resistance before the increase in mass of adipose depots even when mice are fed with regular chow.
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HFD Exacerbates Impairment of Insulin Response in Adipo-MROE Mice
On HFD challenge, adipo-MROE mice showed a higher BW gain than their control-MR littermates ( Figure 4A ). A significant difference was noticed as early as 7 weeks after HFD feeding. Food and calories intake were similar between control-MR and adipo-MROE mice ( Figure S4B-S4D ).
Insulin response was clearly impaired in both groups of mice when challenged with 0.5 U/kg BW of insulin, and adipo-MROE mice displayed virtually no response to insulin at this dose ( Figure 4B ). Increasing the dose for insulin challenge (1 U/kg BW) demonstrated impaired insulin responses in adipo-MROE mice when compared with control-MR littermates ( Figure 4C ). GTT was not significantly different between control-MR and adipo-MROE mice ( Figure 4D ). Thus, increased MR expression in adipocytes exacerbated the detrimental effect of HFD on insulin response in vivo.
Prostaglandin D2 Synthase Is a Novel MR Target in Adipose Tissue of Adipo-MROE Mice
To define MR-modulated pathways in adipocytes, a transcriptional analysis was performed in VAT from adipo-MROE and control-MR mice 3 weeks after MR overexpression induction, when mice showed impaired insulin response but normal BW. One hundred one genes were upregulated, and 246 were downregulated (fold change, >1.5; P<0.05) in VAT of adipo-MROE mice compared with their control-MR littermates (Table S1 ). Most of the upregulated genes were involved in metabolic pathways ( Figure S5 ). We thereafter focused on lipocalinlike prostaglandin D2 synthase (PTGDS), an enzyme recently reported to be involved in adipose tissue pathophysiology, [13] [14] [15] [16] [17] [18] [19] to address its potential role in aldosterone effects. Indeed a link to the aldo/MR pathway is currently unknown. We confirmed the increase of PTGDS gene expression in adipo-MROE mice in VAT from an additional series of adipo-MROE mice ( Figure 5A ). PTGDS mRNA level was also increased in MAF from adipo-MROE mice when compared with MAF from control-MR littermates (relative PTGDS mRNA level: control-MR, 1.0±0.1 and adipo-MROE, 2.4±0.4; n=5 mice per group; P<0.01) suggesting that MR might directly control PTGDS transcription in adipocytes. Importantly, 10 −8 mol/L aldo increased PTGDS mRNA level in adipocytes derived from adipo-MROE SAT ( Figure 5B ). This increase was abolished by coincubation with 10 −6 mol/L MR antagonist spironolactone ( Figure 5B ).
PTGDS Is an MR Target in Adipose Tissues in
Obese db/db Mice PTGDS mRNA level was higher in VAT and SAT of obese db/db mice when compared with their db/+ lean littermates ( Figure 5C ; Figure S6A ). PTGDS mRNA level was also increased in MAF isolated from db/db mice ( Figure S6B ). One month of in vivo treatment with the MR antagonist canrenoate (30 mg/kg per day BW) was effective in blocking the increase in PTGDS expression in SAT, VAT, and MAF of db/db mice ( Figure 5C ; Figure S6A and S6B). The increase of PTGDS mRNA level in VAT and SAT of db/db mice was significantly correlated with the increase of MR mRNA level Figure 5D ; Figure S6C ).
PTGDS Is a Key Actor of Aldosterone Action on Adipocytes
Twenty-four-hour stimulation with 10 −8 mol/L aldo increased PTGDS mRNA level in differentiated 3T3-L1 adipocytes ( Figure 5E ). This was prevented by pharmacological MR antagonist spironolactone (10 −6 mol/L; Figure 5E ). Of note, the glucocorticoid dexamethasone (Dex, 10 −8 mol/L) had no effect ( Figure 5E ). To test whether PTGDS is a direct MR target, we identified a putative glucocorticoid responsive element in the human PTGDS gene promoter located at −425 bp upstream the transcription start site; a luciferase reporter construct, including the region between −794 bp and +36 bp of the PTGDS gene, was responsive to increasing aldo concentrations (ED 50 ≈10 −9 mol/L; Figure 5F ), as well as to corticosterone (ED 50 ≈10 −8 mol/L; Figure S7 ), and it was sensitive to 10 −6 mol/L MR antagonist spironolactone ( Figure S8 ), indicating that PTGDS is an MR-responsive gene which could be activated by either aldo or corticosterone.
To delineate the role of PTGDS in the aldo effects on adipocytes, 3T3-L1 adipocytes were treated with aldo alone or in the presence of AT56, a specific PTGDS inhibitor. 20 Blockade Figure 6A ). AT56 also blunted the increase in mRNA expression of the adipocyte differentiation markers PPARG2 ( Figure 6B ), AP2 ( Figure 6C ), and leptin ( Figure 6D ); no changes were observed using AT56 alone ( Figure 6A-6F) .
We next analyzed the consequences of pharmacological PTGDS inhibition by AT56 on acute insulin stimulation (15 minutes; 10 −7 mol/L) of 3T3-L1 adipocytes treated or not with 10 −8 mol/L aldo. Aldo treatment increased AKT Ser 473 phosphorylation in response to insulin stimulation ( Figure 6E ). This effect was prevented by AT56 cotreatment, whereas AT56 alone had no effect ( Figure 6E ).
PTGDS Is a Target of MR in Human Adipose Tissues
Aldo (10 −8 mol/L) stimulation increased PTGDS mRNA expression in differentiated SW872 human adipocytes ( Figure  S9 ). This increase was prevented by coincubation of aldosterone with the MR antagonist spironolactone (10 −6 mol/L; Figure S9 ).
A 4-fold increase in PTGDS expression was observed in MAF isolated from obese patients when compared with lean subjects ( Figure 7A ). Interestingly, as previously noticed in the db/db mouse model, PTGDS expression was positively correlated with MR expression in MAF of these subjects ( Figure 7B ). In obese patients, VAT showed higher expression levels of PTGDS mRNA when compared with SAT from the same subject ( Figure 7C ). Again, the correlation analysis showed a positive correlation between PTGDS and MR mRNA levels (Spearman correlation, r, 0.65; P<0.0001; Figure 7D ). This underlined the potential importance of the MR/PTGDS interaction in both mice and humans.
Discussion
Our results indicate that, even in the absence of HFD, increased expression of MR in adipose tissue contributes to MetS development with multiple metabolic abnormalities, including visceral obesity and BW gain, glucose intolerance, and insulin resistance, as well as dyslipidemia. Of note, blood pressure was not affected. Moreover, we identified PTGDS as a novel MR target in adipocytes, both in rodent and in human adipocytes, unraveling PTGDS as a new mediator of the adipogenic effects of MR activation. Whether this relates to aldo-or glucocorticoid-mediated MR activation remains to be clarified.
MR and Metabolic Alterations: Potential Benefit of MR Antagonists
MR expression is increased in adipose tissue of various preclinical models of metabolic disease. [6] [7] [8] The present findings suggest that this can be translated to humans, where MR expression is also enhanced in obese patients compared with lean individuals, and in VAT from obese subjects when compared with SAT from the same patient. Recent studies indicate that MR activation is involved in dysregulation of adipose tissue endocrine functions associated with genetic obesity and nutritional challenge and that MR antagonism improves metabolic status in these animal models. In genetically obese db/ db mice, Guo et al 6 reported that pharmacological treatment with the selective MR antagonist eplerenone for 16 weeks reversed the obesity-related changes in adipose tissue gene expression. Short-term eplerenone administration (3 weeks) in db/db and ob/ob mice also showed improved insulin sensitivity, whereas MR antagonism restored the dysregulation in adipose tissue gene expression in both models. 7 Twelve-week eplerenone administration improved insulin resistance and dyslipidemia, and it blunted VAT mass increase and reduced adipocyte size in mice fed with high-fat and high-fructose diet.
21 MR antagonist spironolactone blunted the increase in HOMA index and impaired glucose tolerance induced by high-fructose diet associated with aldo infusion. 22 A recent report indicates that transgenic mice with systemic and constitutive MR overexpression showed paradoxical resistance to obesity and metabolic alterations induced by HFD, a result difficult to reconcile with the beneficial effects observed when using various MR antagonists. 23 The pharmacological approach could not discriminate between direct consequences of MR blockade in adipose tissue and the effect of systemic MR antagonism in other tissues involved in MetS, such as vasculature, pancreas, liver, and skeletal muscle. The targeted approach used in this study allowed us to assess the specific role of MR in adipocytes. Adipo-MROE mice exhibit in fact a moderate increase of fat MR expression, which mimics the fat MR increase we and others [6] [7] [8] have observed in several obese mouse models (db/db, ob/ob, and HFD) and in obese humans as reported here.
MR Activation Alters Adipocyte Functions
MR activation in 3T3-L1 and 3T3-F442A white preadipocytes induces major changes in morphological, biochemical, and molecular markers of adipose differentiation. [6] [7] [8] [9] [24] [25] [26] The use of specific MR antagonists or siRNA directed against MR mRNA showed that MR, but not glucocorticoid receptor, was involved in aldo-mediated induction of adipogenic transcriptional pathway, leading to an upregulation of C/EBPα and PPARG gene expression, with subsequent increase of intracellular triglycerides and increased expression of adipokines. 9 In brown adipocyte cell lines obtained from constitutive glucocorticoid receptor and MR new born mice, Hoppmann et al 27 showed that MR knockout cells completely failed to accumulate lipids during early differentiation. Caprio et al 9 showed that pharmacological blockade of MR inhibited critical pathways for adipocyte differentiation in 3T3-L1 cells, by interfering in PPARG expression. Specifically, they showed that MR antagonism was able to blunt ex vivo differentiation of human primary preadipocytes obtained from different fat depots. 9 Although initial studies indicated aldo as the key factor for promoting adipogenesis, 28,29 more recent studies have shown a pivotal role of MR activation per se either by mineralocorticoids or glucocorticoids. 9 Hirata et al 10 demonstrated in fact that the endogenous rodent glucocorticoid corticosterone is able to activate MR in 3T3-L1 adipocytes. In our ex vivo experiments, we used aldo and not glucocorticoids to avoid the potential confounding effect of glucocorticoid receptor activation. Because of low expression of 11HSD2 enzyme in adipose tissue and the excess of circulating glucocorticoids over aldo in vivo, it is tempting to speculate that glucocorticoids are the main endogenous ligands of adipocyte MR. The association of primary aldosteronism and metabolic alterations suggests, however, that aldo could directly act on MR in adipose tissue. 5 Furthermore, it has been demonstrated that adipocytes produce aldo, 30 supporting a local paracrine MR activation by aldo in adipose tissue. Thus, MR differs from the other steroid receptors in that it binds to 2 physiological ligands; whether aldo or glucocorticoids are the natural MR ligands in adipocytes in vivo remains an open question. Understanding the structural determinants of tissue-and ligand-specific MR activation is required to provide the basis for the development of novel therapeutic and tissue-specific MR ligands.
Molecular Targets of MR in Adipocytes
Molecular targets of MR in nonadrenal cells, including adipocytes, are unknown. Besides genes involved in adipocyte homeostasis and metabolic alterations, such as adiponectin, leptin, PPARG, and resistin, little is known about the specific molecular targets of MR in adipocytes. We performed a transcriptomic analysis on VAT of adipo-MROE mice after 3 weeks induction of MR overexpression. Among the genes with dysregulated expression, we focused on PTGDS, a gene involved in metabolic alterations and not previously identified as an MR target. We showed that PTGDS expression is upregulated on MR activation in differentiated 3T3-L1 cells, in adipocytes derived from the vascular fraction of adipo-MROE fat and in db/db mice. Interestingly, under every experimental condition, PTGDS and MR expression levels were strongly correlated. A nonclassical glucocorticoid responsive element is present in the PTGDS promoter, which is functionally activated by MR as demonstrated in the reporter assay performed in this study. Pharmacological MR antagonism blunted adipose PTGDS expression both ex vivo in cultured adipocytes and in vivo in db/db mice. Importantly, PTGDS is an MR target not only in cultured human adipocytes but also in human adipose tissues, as suggested by the correlation between MR expression and PTGDS expression in human mature adipocytes and fat depots.
Further studies are needed to determine how PTGDS participates in adipogenesis and insulin resistance induced by adipocyte MR activation. PTGDS has at least 2 known functions: it synthesizes D-series prostaglandins and can also act as a carrier of lipophilic molecules. PTGDS has been reported to be proadipogenic via the synthesis of prostaglandin-2 and its metabolite ∆2-PGJ2, a ligand of PPARG, able to activate adipogenesis ex vivo.
18 Transgenic mice overexpressing PTGDS become obese on HFD as observed in adipo-MROE mice. 31 The role of PTGDS in insulin sensitivity/glucose tolerance is however controversial. Virtue et al 19 reported that mice lacking PTGDS had improved glucose tolerance when fed with HFD, despite similar degree of insulin resistance compared with wild-type mice. On the other hand, Ragolia et al 14 reported opposite results, indicating that adipocyte size is increased in PTGDS knockout mice that become glucose intolerant and insulin resistant. The reasons for such discrepancies are unclear. Therefore, PTGDS may have 2 faces: to promote adipogenesis by modulating PPARG and to increase insulin sensitivity by enhancing glucose uptake via increased GLUT4 translocation to the membrane in skeletal muscle. 16 Such different effects may depend on local factors and metabolic environment. Moreover, we showed that AT56, a specific inhibitor of PTGDS enzymatic activity, blunted aldo effects in adipocytes, indicating that PTGDS may have a key role in aldosterone/MR-induced adipose tissue function. In vivo, increased PTGDS expression in adipocytes overexpressing MR might therefore contribute to adipogenic effects of MR and to modulation of insulin sensitivity in a tissue-specific manner. Further studies are required to evaluate the specific pathophysiological role of PTGDS in metabolic effects related to MR activation.
In conclusion, we showed that MR expression is increased in VAT in a preclinical mouse model of MetS and in obese patients. In vivo conditional upregulation of MR in mouse adipocytes led to increased weight and fat mass, insulin resistance, and MetS features. In addition, we identified PTGDS as a novel downstream target of MR in adipocytes. Targeting this pathway may be an interesting therapeutic strategy that warrants further investigation.
Perspectives
Our data support the concept that overactivation of MR in adipocytes participates in the development of MetS. These findings support the rationale for further clinical studies to evaluate the potential benefit of MR antagonism in patients with adipose tissue overexpressing MR, such as in obese individuals or those with MetS. Moreover, identification of PTGDS as a novel MR target involved in aldosterone-mediated adipogenesis should stimulate further studies analyzing the therapeutic potential of PTGDS inhibitors in this context. What Is New?
• We provide key insights supporting the rationale that mineralocorticoid receptor (MR) is a therapeutic target in metabolic syndrome (MetS).
• We identify prostaglandin D2 synthase as a novel target of adipocyte MR activation, which is mandatory for the adipogenesis process induced by aldosterone.
What Is Relevant?
• Our data support the concept that overactivation of MR in adipocytes participates in the development of MetS. These findings support the rationale for further clinical studies to evaluate the potential benefit of MR antagonism in patients with adipose tissue overexpressing MR, such as obese individuals or those with MetS.
Summary
We showed that MR expression is increased in visceral adipose tissue in a preclinical mouse model of MetS and in obese patients.
In vivo conditional upregulation of MR in mouse adipocyte led to an increase in body weight, in particular the fat mass, and to the onset of insulin resistance and clinical features of MetS. In addition, we identified prostaglandin D2 synthase as a novel downstream target of MR in adipocytes that is involved in the adipogenic effects of aldosterone.
ONLINE SUPPLEMENT
Adipocyte mineralocorticoid receptor activation leads to metabolic syndrome and induction of Prostaglandin D2 Synthase. 
Riccardo
Supplemental Methods
Mouse model with conditional MR overexpression in adipocytes. A novel mouse strain allowing inducible adipocyte-specific transgene expression (aP2-rtTA mice) was generated by targeted transgenesis in the permissive hprt locus as previously described 1 . Briefly, the rtTA-M2 trans-activator was sub cloned after the aP2 promoter, a generous gift from Prof. B. Spiegelman 2 , and the transgene was introduced as a single copy into the hprt locus by homologous recombination in embryonic stem (ES) cells. Targeted aP2-rtTA targeted ES cells were then used to generate transgenic mice. The new aP2-rtTA (adipo-mouse) trans-activator mouse strain was thereafter crossed with the previously characterized tetO-hMR (hMRmouse) mouse strain 3 to generate aP2-rtTA/tetO-hMR (Adipo-MROE) mice, allowing inducible adipocyte-specific MR overexpression upon doxycycline (Dox) administration. To induce transgene expression, 8-week old mice, matched for age and weight, received 2g/L of dox in drinking water (DOX, #D3447 Sigma-Aldrich, Saint Quentin Fallavier, France). Littermates (i.e., mono transgenic, tetO-hMR or aP2-rtTA, or wild type) were used as controls (Control-MR) and received DOX like Adipo-MROE mice ( Figure S1 ).
Obese db/db mice. 8 weeks old male db/db obese mice and lean control male db/+ heterozygous littermates were purchased from Jackson Laboratories (#B6.BKS(D)-Leprdb/J, Bar Harbor, ME -USA).
Food and calories intake. Food intake were measured on mice kept in individual cages (Phymep Marty Technology, Paris, France) for 1 week: three days for habituation and four days of actual measurements. Calories were deducted by multiplying food intake for energy density of each diet.
Blood pressure measurement. Systolic blood pressure (SBP) was measured by tail cuff plethysmography in trained conscious mice. Ten measurements per mice were taken every day between 10 a.m. and 12 a.m. during 5 days using a BP2000 Visitech model (Bioseb, Vitrolles, France) as described 4 .
Biochemical and assays. Glycaemia was determined in blood samples using the Accu-check Aviva glucometer (Roche Diagnostics). Insulin concentration was quantified in plasma samples collected during GTT analysis by the use of the Millipore Rat/Mouse Insulin ELISA kit (Merck KGaA, Darmstadt, Germany).
Total triglycerides, total cholesterol and HDL cholesterol were quantified in plasma samples using Konelab 60 Prime Station with appropriate kits (Thermo Scientific, Waltham, MA -USA).
Aldosterone concentrations were determined in plasma from Adipo-AMROE and Control-MR mice by enzyme immunoassay (EIA) (Cayman Chemical, Ann Arbor, MI, USA) according to the manufacturer´s instructions.
Mouse 3T3-L1 preadipocytes. 3T3-L1 cells (#CL-173
LGC, Molsheim, France) were grown in monolayer culture in DMEM and properly differentiated as described in LGC data sheet 5 . Differentiated 3T3-L1 adipocytes were starved from serum for 24h before any stimulation. We performed two different set of experiments in 3T3-L1 adipocytes: a 24h stimulation with vehicle (veh, 0.01% ethanol), aldo (10 -8 M), a combination of aldo and MR antagonist spironolactone (10 -6 M, Sigma-Aldrich) or spironolactone alone, and a 24h stimulation with veh, aldo, a combination of aldo and PTGDS specific inhibitor AT56 (5x10 -5 M, # 3531 Tocris, Bristol, UK) or AT56 alone. Formalin fixed cells were stained with Oil Red as described 6 . To extract the incorporated Oil Red O dye, absolute isopropanol was added to the stained cell culture dish and shaken at room temperature for 15 min. Signal was measured at 510 nm. N=7 set of independent experiments. Human SW872 preadipocytes. Human SW872 (#HTB-92, LGC) liposarcoma cells were grown in monolayer culture in 10%-FBS DMEM and differentiated as previously described for 3T3-L1 cells. Differentiated SW872 adipocytes were stimulated for 24h with vehicle, aldo (10 -8 M) or a combination of aldo and MR antagonist spironolactone (MRA, 10 -6 M). N=5 set of independent experiments.
Primary culture of adipocytes derived from SAT of adipo-MROE mice. The stromal vascular fraction was isolated from SAT obtained from 8 to 10 adipo-MROE mice and differentiated as previously described for humans 7 . HMR transgene expression was induced by 72h incubation with 1µg/mL Dox in the culture medium. Differentiated adipocytes were stimulated for 24h with vehicle, aldo (10 -8 M) or aldo in combination with MR antagonist spironolactone (10 -6 M) or spironolactone alone. N=3 set of independent experiments. MAF isolation in mice. VAT biopsies were obtained from mice and mouse MAF was extracted as described for human MAF.
Adipocytes size analysis. Adipose tissue were fixed in 4% paraformaldehyde and paraffin-embedded. 6µm sections were stained with hematoxylin solution (#MHS16, Sigma-Aldrich). Two photographs (x20) per section were taken and analyzed with ImageJ software. In every picture each adipocyte perimeter was manually tagged and surface was calculated by the software. Pictures were taken and analyzed by a blinded investigator. Only the researcher had access to sample identification list.
RNA extraction and quantitative RT-PCR.
Total RNA was extracted from tissues and cultured cells by using respectively the RNeasy Mini Kit (Qiagen, Courtaboeuf, France) and the TRIZOL® reagent (Life Technologies, Saint Aubin, France). After DNase treatment (Qiagen) reverse transcription and quantitative PCR (qPCR,sybr green) were performed as reported 8 . The mRNA levels were normalized using a series of housekeeping genes, 18S, β-2-microglobulina and ubiquitin C , and they are expressed as fold increase of control condition. Primer sequences are listed in table S2 for human and in table S3 for mouse.
PTGDS reporter assay.
A mouse genomic fragment spanning the area -794/+36 bp relative to PTGDS transcription start site was amplified by PCR using a proofreading polymerase (PfuUltra II, Stratagene, Amsterdam, Netherlands) using oligonucleotides flanked by KpnI and HindIII sites. The purified product was cloned into pGL4.10luc2 vector (Promega, Charbonnieres, France), which contains a promoterless firefly luciferase cDNA. The resulting vector, PTGDS(-794/+36)-luc, was co-transfected into Cos-7 cells together with mouse MR and a vector containing Renilla luciferase under the control of a SV40 constitutive promoter. Cells were kept in medium supplemented with charcoal-stripped fetal bovine serum (Life Technologies) and treated overnight with vehicle, and the indicated concentration of aldo and/or MR antagonist spironolactone. Firefly and Renilla luciferase activities were determined using a commercial kit (Dual-glo luciferase assay system, Reverse:
Reverse:
5'-AGATGAGTATGCCTGCCGTG-3'
5'-TCATCCAATCCAAATGCGGC-3' MR NR3C2, nuclear receptor subfamily 3, group C, member 2
Forward:
5'-TTATATAAGGACGCGCCGGG-3'
5'-GACGATCACAGCGATCCAC-3' The conditional Adipo-MROE mouse strain is issued from the crossbreed of the previously described "tetOhMR" strain and "aP2-rtTA" strain. The TetO-hMR is a construct made of the bacterial "tetO" operator sequence fused to human MR coding sequence. AP2-rtTA is made by adipocyte specific aP2 gene promoter sequence fused to rtTA coding sequence. The presence of both transgenes in Adipo-MROE mice allows the transcription of RTTA protein in fat and transcription of transgenic MR in the presence of Doxycycline (2g/L, Dox). Wild type (WT) and mono-transgenic tetO-hMR or aP2-rtTA littermates were used as control (Control-MR). Total MR (t-MR) (endogenous+exogenous) and endogenous MR (mMR) mRNA expression levels were assessed in (B) SAT, (C) VAT and (D) MAF of Adipo-MROE mice (n=8) and their Control-MR littermates (n=10). Bars represent means ± SEM. *P < 0.05, **P < 0.01, Mann-Whitney test. PTGDS mRNA levels measured in differentiated SW872 human adipocytes, upon 24h stimulation with Veh, 10-8M Aldo (Aldo) or Aldo plus 10-6M spironolactone (Aldo+MRA). Bars represent means ± SEM, n=5 independent experiments, **P < 0.01, one-way ANOVA test followed by Newman-Keuls test.
